Global Osteoporosis Treatment Market By Treatment (Bisphosphonates – Alendronate (Binosto, Fosamax), Ibandronate (Boniva), Risedronate (Actonel, Atelvia), Zoledronic acid, Denosumab, Hormone-related therapy, Bone-building medications – Teriparatide, Abaloparatide, Romosozumab, Others); By Route of Administration (Oral, Intravenous); By Gender (Men, Women); By Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospitals and clinics); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Over the period of time, our body is prone to witness several issues due to wear and tear, and also if not taken care properly. Osteoporosis happens to be one such disease where the bones turn out to be weak and brittle. While the human body on a continuous level absorbs and replaces the tissue of bone and when starts suffering from the osteoporosis, creation of new bone fails to keep up with old bone removal. Majority of people witness no symptoms until and unless they suffer from the bone fracture. The treatment of the osteoporosis is inclusive of medication, fantastic diet and certain exercise to aid in stopping any future bone loss or even provide strength to those bones that are utterly weak. As stated above, there are no main symptoms of osteoporosis, especially in the pre-liminary stages of bone loss. Though major symptoms of this ailment are pain in the back that can be caused by a vertebra that is either broken or collapsed, loss of height over the period, along with the posture that is stooped. When one is suffering from osteoporosis, their bones are likely to break easily. Meanwhile there are several causes of osteoporosis. One major cause of this disease is lifelong lack of calcium. Low intake of calcium causes the bone density to go down, premature bone loss and enhanced risk of fractures. Owing to multiple factors, the global osteoporosis treatment market is growing aggressively.
In terms of revenue, the global osteoporosis treatment market was valued at US$ 14.05 Bn in 2021 growing at a CAGR of 3.9% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Osteoporosis Treatment Market Revenue & Forecast, (US$ Million), 2015 – 2030
Treatment Outlook
Based on the treatment outlook, the global osteoporosis treatment market has been segmented into bisphosphonates, denosumab, hormone-related therapy, bone-building medications and others. The bisphosphonates segment is further bifurcated into alendronate (binosto, fosamax), ibandronate (boniva), risedronate (Actonel, atelvia) and zoledronic acid. On the other hand, the bone-building medications segment is divided again into teriparatide, abaloparatide, and romosozumab. The bisphosphonates segment makes majority of money for the market. Bisphosphonates happen to be a class of drugs that treats osteoporosis by simply curbing the bone loss density. As these drugs have two phosphonate groups, they are known as bisphosphonates.
Region Outlook
On the basis of the region, the continent of North America emerges on the top of the list in terms of making money for the global osteoporosis treatment market in the year 2021. According to the reports, around 10 million people in the United States are suffering from this disease that makes bones brittle, while nearly 44 million have lower density in bone, which is why they are prone to suffer from more serious injuries. Though, availability of advanced treatment and highly efficient medications is the helping the growth of the market.
Competitive Landscape
The report provides both, qualitative and quantitative research of global osteoporosis treatment market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the key market participants operating in the global osteoporosis treatment market are:
- Amgen Inc
- DAIICHI SANKYO COMPANY, LIMITED
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Ligand Pharmaceuticals Incorporated
- Merck & Co., Inc
- Novartis AG
- Pfizer Inc.
- Radius Health, Inc.
- Sanofi-aventis U.S. LLC
- Teva Pharmaceuticals Industries Ltd.
- Other Market Participants
Global Osteoporosis Treatment Market:
By Treatment
- Bisphosphonates
- Alendronate (Binosto, Fosamax)
- Ibandronate (Boniva)
- Risedronate (Actonel, Atelvia)
- Zoledronic acid
- Denosumab
- Hormone-related therapy
- Bone-building medications
- Teriparatide
- Abaloparatide
- Romosozumab
- Others
By Route of Administration
- Oral
- Intravenous
By Gender
- Men
- Women
By Distribution Channel
- Online Pharmacies
- Retail Pharmacies
- Hospitals and clinics
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2020
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 - 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Osteoporosis Treatment Market
6. Market Synopsis:Â
Osteoporosis Treatment Market
7. Osteoporosis Treatment Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in
Osteoporosis Treatment Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Osteoporosis Treatment Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Osteoporosis Treatment Market
8. Global Osteoporosis Treatment Market Analysis and Forecasts, 2022
- 2030
8.1. Overview
8.1.1. Global
Osteoporosis Treatment Market Revenue (US$ Mn)
8.2. Global
Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment
8.2.1. Bisphosphonates
(Definition, Market Estimation and Penetration, 2015 - 2021, Market Estimation
(2015 - 2021), Market Forecast (2022 - 2030), Compound Annual Growth Rate
(CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East
and Africa, Latin America) and Information on Alendronate (Binosto, Fosamax),
Ibandronate (Boniva), Risedronate (Actonel, Atelvia), Zoledronic acid)
8.2.1.1. Alendronate (Binosto, Fosamax)
8.2.1.2. Ibandronate (Boniva)
8.2.1.3. Risedronate (Actonel, Atelvia)
8.2.1.4. Zoledronic acid
8.2.2. Denosumab
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2021
8.2.2.3. Market Forecast, 2022 - 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2021
8.2.2.5.1.2. Market
Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2021
8.2.2.5.2.2. Market
Forecast, 2022 - 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2021
8.2.2.5.3.2. Market
Forecast, 2022 - 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2021
8.2.2.5.4.2. Market
Forecast, 2022 - 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2021
8.2.2.5.5.2. Market
Forecast, 2022 - 2030
8.2.3. Hormone-related
therapy
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2021
8.2.3.3. Market Forecast, 2022 - 2030
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2021
8.2.3.5.1.2. Market
Forecast, 2022 - 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2021
8.2.3.5.2.2. Market
Forecast, 2022 - 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2021
8.2.3.5.3.2. Market
Forecast, 2022 - 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2021
8.2.3.5.4.2. Market
Forecast, 2022 - 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2021
8.2.3.5.5.2. Market
Forecast, 2022 - 2030
8.2.4. Bone-building
medications (Definition, Market Estimation and Penetration, 2015 - 2021, Market
Estimation (2015 - 2021), Market Forecast (2022 - 2030), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Teriparatide, Abaloparatide,
Romosozumab)
8.2.4.1. Teriparatide
8.2.4.2. Abaloparatide
8.2.4.3. Romosozumab
8.2.5. Others
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 - 2021
8.2.5.3. Market Forecast, 2022 - 2030
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market
Estimation, 2015 - 2021
8.2.5.5.1.2. Market
Forecast, 2022 - 2030
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 - 2021
8.2.5.5.2.2. Market
Forecast, 2022 - 2030
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market
Estimation, 2015 - 2021
8.2.5.5.3.2. Market
Forecast, 2022 - 2030
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 - 2021
8.2.5.5.4.2. Market
Forecast, 2022 - 2030
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market
Estimation, 2015 - 2021
8.2.5.5.5.2. Market
Forecast, 2022 - 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By
Treatment
9. Global Osteoporosis Treatment Market Analysis and Forecasts, 2022
- 2030
9.1. Overview
9.2. Global
Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
9.2.1. Oral
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2021
9.2.1.3. Market Forecast, 2022 - 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2021
9.2.1.5.1.2. Market
Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2021
9.2.1.5.2.2. Market
Forecast, 2022 - 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2021
9.2.1.5.3.2. Market
Forecast, 2022 - 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2021
9.2.1.5.4.2. Market
Forecast, 2022 - 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2021
9.2.1.5.5.2. Market
Forecast, 2022 - 2030
9.2.2. Intravenous
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2021
9.2.2.3. Market Forecast, 2022 - 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 - 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 - 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 - 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 - 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By Route
of Administration
10. Global Osteoporosis Treatment Market Analysis and Forecasts, 2022
- 2030
10.1. Overview
10.2. Global
Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Gender
10.2.1. Men
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2021
10.2.1.3. Market Forecast, 2022 - 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 - 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 - 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 - 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 - 2030
10.2.2. Women
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2021
10.2.2.3. Market Forecast, 2022 - 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2021
10.2.2.5.1.2. Market
Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2021
10.2.2.5.2.2. Market
Forecast, 2022 - 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2021
10.2.2.5.3.2. Market
Forecast, 2022 - 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2021
10.2.2.5.4.2. Market
Forecast, 2022 - 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2021
10.2.2.5.5.2. Market
Forecast, 2022 - 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By
Gender
11. Global Osteoporosis Treatment Market Analysis and Forecasts, 2022
- 2030
11.1. Overview
11.2. Global
Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
11.2.1. Online
Pharmacies
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2021
11.2.1.3. Market Forecast, 2022 - 2030
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2021
11.2.1.5.1.2. Market
Forecast, 2022 - 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2021
11.2.1.5.2.2. Market
Forecast, 2022 - 2030
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2021
11.2.1.5.3.2. Market
Forecast, 2022 - 2030
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2021
11.2.1.5.4.2. Market
Forecast, 2022 - 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2021
11.2.1.5.5.2. Market
Forecast, 2022 - 2030
11.2.2. Retail
Pharmacies
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2021
11.2.2.3. Market Forecast, 2022 - 2030
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2021
11.2.2.5.1.2. Market
Forecast, 2022 - 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2021
11.2.2.5.2.2. Market
Forecast, 2022 - 2030
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2021
11.2.2.5.3.2. Market
Forecast, 2022 - 2030
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2021
11.2.2.5.4.2. Market
Forecast, 2022 - 2030
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2021
11.2.2.5.5.2. Market
Forecast, 2022 - 2030
11.2.3. Hospitals
and Clinics
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2021
11.2.3.3. Market Forecast, 2022 - 2030
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 - 2021
11.2.3.5.1.2. Market
Forecast, 2022 - 2030
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 - 2021
11.2.3.5.2.2. Market
Forecast, 2022 - 2030
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 - 2021
11.2.3.5.3.2. Market
Forecast, 2022 - 2030
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 - 2021
11.2.3.5.4.2. Market
Forecast, 2022 - 2030
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 - 2021
11.2.3.5.5.2. Market
Forecast, 2022 - 2030
11.3. Key
Segment for Channeling Investments
11.3.1. By
Distribution Channel
12. North America Osteoporosis Treatment Market Analysis and
Forecasts, 2022 - 2030
12.1. Overview
12.1.1. North
America Osteoporosis Treatment Market Revenue (US$ Mn)
12.2. North
America Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment
12.2.1. Bisphosphonates
12.2.1.1. Alendronate (Binosto, Fosamax)
12.2.1.2. Ibandronate (Boniva)
12.2.1.3. Risedronate (Actonel, Atelvia)
12.2.1.4. Zoledronic acid
12.2.2. Denosumab
12.2.3. Hormone-related
therapy
12.2.4. Bone-building
medications
12.2.4.1. Teriparatide
12.2.4.2. Abaloparatide
12.2.4.3. Romosozumab
12.2.5. Others
12.3. North
America Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
12.3.1. Oral
12.3.2. Intravenous
12.4. North
America Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Gender
12.4.1. Men
12.4.2. Women
12.5. North America
Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.1. Online
Pharmacies
12.5.2. Retail
Pharmacies
12.5.3. Hospitals
and Clinics
12.6. North
America Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By
Country
12.6.1. U.S
12.6.1.1. U.S Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.6.1.1.1. Bisphosphonates
12.6.1.1.1.1. Alendronate
(Binosto, Fosamax)
12.6.1.1.1.2. Ibandronate
(Boniva)
12.6.1.1.1.3. Risedronate
(Actonel, Atelvia)
12.6.1.1.1.4. Zoledronic
acid
12.6.1.1.2. Denosumab
12.6.1.1.3. Hormone-related therapy
12.6.1.1.4. Bone-building medications
12.6.1.1.4.1. Teriparatide
12.6.1.1.4.2. Abaloparatide
12.6.1.1.4.3. Romosozumab
12.6.1.1.5. Others
12.6.1.2. U.S Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
12.6.1.2.1. Oral
12.6.1.2.2. Intravenous
12.6.1.3. U.S Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
12.6.1.3.1. Men
12.6.1.3.2. Women
12.6.1.4. U.S Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.6.1.4.1. Online Pharmacies
12.6.1.4.2. Retail Pharmacies
12.6.1.4.3. Hospitals and Clinics
12.6.2. Canada
12.6.2.1. Canada Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.6.2.1.1. Bisphosphonates
12.6.2.1.1.1. Alendronate
(Binosto, Fosamax)
12.6.2.1.1.2. Ibandronate
(Boniva)
12.6.2.1.1.3. Risedronate
(Actonel, Atelvia)
12.6.2.1.1.4. Zoledronic
acid
12.6.2.1.2. Denosumab
12.6.2.1.3. Hormone-related therapy
12.6.2.1.4. Bone-building medications
12.6.2.1.4.1. Teriparatide
12.6.2.1.4.2. Abaloparatide
12.6.2.1.4.3. Romosozumab
12.6.2.1.5. Others
12.6.2.2. Canada Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
12.6.2.2.1. Oral
12.6.2.2.2. Intravenous
12.6.2.3. Canada Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
12.6.2.3.1. Men
12.6.2.3.2. Women
12.6.2.4. Canada Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.6.2.4.1. Online Pharmacies
12.6.2.4.2. Retail Pharmacies
12.6.2.4.3. Hospitals and Clinics
12.6.3. Mexico
12.6.3.1. Mexico Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
12.6.3.1.1. Bisphosphonates
12.6.3.1.1.1. Alendronate
(Binosto, Fosamax)
12.6.3.1.1.2. Ibandronate
(Boniva)
12.6.3.1.1.3. Risedronate
(Actonel, Atelvia)
12.6.3.1.1.4. Zoledronic
acid
12.6.3.1.2. Denosumab
12.6.3.1.3. Hormone-related therapy
12.6.3.1.4. Bone-building medications
12.6.3.1.4.1. Teriparatide
12.6.3.1.4.2. Abaloparatide
12.6.3.1.4.3. Romosozumab
12.6.3.1.5. Others
12.6.3.2. Mexico Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
12.6.3.2.1. Oral
12.6.3.2.2. Intravenous
12.6.3.3. Mexico Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
12.6.3.3.1. Men
12.6.3.3.2. Women
12.6.3.4. Mexico Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.6.3.4.1. Online Pharmacies
12.6.3.4.2. Retail Pharmacies
12.6.3.4.3. Hospitals and Clinics
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Osteoporosis Treatment Market Revenue
(US$ Mn) and Forecasts, By Treatment
12.6.4.1.1. Bisphosphonates
12.6.4.1.1.1. Alendronate
(Binosto, Fosamax)
12.6.4.1.1.2. Ibandronate
(Boniva)
12.6.4.1.1.3. Risedronate
(Actonel, Atelvia)
12.6.4.1.1.4. Zoledronic
acid
12.6.4.1.2. Denosumab
12.6.4.1.3. Hormone-related therapy
12.6.4.1.4. Bone-building medications
12.6.4.1.4.1. Teriparatide
12.6.4.1.4.2. Abaloparatide
12.6.4.1.4.3. Romosozumab
12.6.4.1.5. Others
12.6.4.2. Rest of North America Osteoporosis Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
12.6.4.2.1. Oral
12.6.4.2.2. Intravenous
12.6.4.3. Rest of North America Osteoporosis Treatment Market Revenue
(US$ Mn) and Forecasts, By Gender
12.6.4.3.1. Men
12.6.4.3.2. Women
12.6.4.4. Rest of North America Osteoporosis Treatment Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
12.6.4.4.1. Online Pharmacies
12.6.4.4.2. Retail Pharmacies
12.6.4.4.3. Hospitals and Clinics
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Treatment
12.7.3. By
Route of Administration
12.7.4. By
Gender
12.7.5. By
Distribution Channel
13. Europe Osteoporosis Treatment Market Analysis and Forecasts, 2022
- 2030
13.1. Overview
13.1.1. Europe
Osteoporosis Treatment Market Revenue (US$ Mn)
13.2. Europe
Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Treatment
13.2.1. Bisphosphonates
13.2.1.1. Alendronate (Binosto, Fosamax)
13.2.1.2. Ibandronate (Boniva)
13.2.1.3. Risedronate (Actonel, Atelvia)
13.2.1.4. Zoledronic acid
13.2.2. Denosumab
13.2.3. Hormone-related
therapy
13.2.4. Bone-building
medications
13.2.4.1. Teriparatide
13.2.4.2. Abaloparatide
13.2.4.3. Romosozumab
13.2.5. Others
13.3. Europe Osteoporosis
Treatment Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.3.1. Oral
13.3.2. Intravenous
13.4. Europe
Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Gender
13.4.1. Men
13.4.2. Women
13.5. Europe
Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.1. Online
Pharmacies
13.5.2. Retail
Pharmacies
13.5.3. Hospitals
and Clinics
13.6. Europe
Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.6.1.1.1. Bisphosphonates
13.6.1.1.1.1. Alendronate
(Binosto, Fosamax)
13.6.1.1.1.2. Ibandronate
(Boniva)
13.6.1.1.1.3. Risedronate
(Actonel, Atelvia)
13.6.1.1.1.4. Zoledronic
acid
13.6.1.1.2. Denosumab
13.6.1.1.3. Hormone-related therapy
13.6.1.1.4. Bone-building medications
13.6.1.1.4.1. Teriparatide
13.6.1.1.4.2. Abaloparatide
13.6.1.1.4.3. Romosozumab
13.6.1.1.5. Others
13.6.1.2. France Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.1.2.1. Oral
13.6.1.2.2. Intravenous
13.6.1.3. France Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
13.6.1.3.1. Men
13.6.1.3.2. Women
13.6.1.4. France Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.1.4.1. Online Pharmacies
13.6.1.4.2. Retail Pharmacies
13.6.1.4.3. Hospitals and Clinics
13.6.2. The UK
13.6.2.1. The UK Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.6.2.1.1. Bisphosphonates
13.6.2.1.1.1. Alendronate
(Binosto, Fosamax)
13.6.2.1.1.2. Ibandronate
(Boniva)
13.6.2.1.1.3. Risedronate
(Actonel, Atelvia)
13.6.2.1.1.4. Zoledronic
acid
13.6.2.1.2. Denosumab
13.6.2.1.3. Hormone-related therapy
13.6.2.1.4. Bone-building medications
13.6.2.1.4.1. Teriparatide
13.6.2.1.4.2. Abaloparatide
13.6.2.1.4.3. Romosozumab
13.6.2.1.5. Others
13.6.2.2. The UK Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.2.2.1. Oral
13.6.2.2.2. Intravenous
13.6.2.3. The UK Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
13.6.2.3.1. Men
13.6.2.3.2. Women
13.6.2.4. The UK Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.2.4.1. Online Pharmacies
13.6.2.4.2. Retail Pharmacies
13.6.2.4.3. Hospitals and Clinics
13.6.3. Spain
13.6.3.1. Spain Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.6.3.1.1. Bisphosphonates
13.6.3.1.1.1. Alendronate
(Binosto, Fosamax)
13.6.3.1.1.2. Ibandronate
(Boniva)
13.6.3.1.1.3. Risedronate
(Actonel, Atelvia)
13.6.3.1.1.4. Zoledronic
acid
13.6.3.1.2. Denosumab
13.6.3.1.3. Hormone-related therapy
13.6.3.1.4. Bone-building medications
13.6.3.1.4.1. Teriparatide
13.6.3.1.4.2. Abaloparatide
13.6.3.1.4.3. Romosozumab
13.6.3.1.5. Others
13.6.3.2. Spain Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.3.2.1. Oral
13.6.3.2.2. Intravenous
13.6.3.3. Spain Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
13.6.3.3.1. Men
13.6.3.3.2. Women
13.6.3.4. Spain Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.3.4.1. Online Pharmacies
13.6.3.4.2. Retail Pharmacies
13.6.3.4.3. Hospitals and Clinics
13.6.4. Germany
13.6.4.1. Germany Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.6.4.1.1. Bisphosphonates
13.6.4.1.1.1. Alendronate
(Binosto, Fosamax)
13.6.4.1.1.2. Ibandronate
(Boniva)
13.6.4.1.1.3. Risedronate
(Actonel, Atelvia)
13.6.4.1.1.4. Zoledronic
acid
13.6.4.1.2. Denosumab
13.6.4.1.3. Hormone-related therapy
13.6.4.1.4. Bone-building medications
13.6.4.1.4.1. Teriparatide
13.6.4.1.4.2. Abaloparatide
13.6.4.1.4.3. Romosozumab
13.6.4.1.5. Others
13.6.4.2. Germany Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.4.2.1. Oral
13.6.4.2.2. Intravenous
13.6.4.3. Germany Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
13.6.4.3.1. Men
13.6.4.3.2. Women
13.6.4.4. Germany Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.4.4.1. Online Pharmacies
13.6.4.4.2. Retail Pharmacies
13.6.4.4.3. Hospitals and Clinics
13.6.5. Italy
13.6.5.1. Italy Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
13.6.5.1.1. Bisphosphonates
13.6.5.1.1.1. Alendronate
(Binosto, Fosamax)
13.6.5.1.1.2. Ibandronate
(Boniva)
13.6.5.1.1.3. Risedronate
(Actonel, Atelvia)
13.6.5.1.1.4. Zoledronic
acid
13.6.5.1.2. Denosumab
13.6.5.1.3. Hormone-related therapy
13.6.5.1.4. Bone-building medications
13.6.5.1.4.1. Teriparatide
13.6.5.1.4.2. Abaloparatide
13.6.5.1.4.3. Romosozumab
13.6.5.1.5. Others
13.6.5.2. Italy Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.5.2.1. Oral
13.6.5.2.2. Intravenous
13.6.5.3. Italy Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
13.6.5.3.1. Men
13.6.5.3.2. Women
13.6.5.4. Italy Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.5.4.1. Online Pharmacies
13.6.5.4.2. Retail Pharmacies
13.6.5.4.3. Hospitals and Clinics
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Osteoporosis Treatment Market Revenue (US$
Mn) and Forecasts, By Treatment
13.6.6.1.1. Bisphosphonates
13.6.6.1.1.1. Alendronate
(Binosto, Fosamax)
13.6.6.1.1.2. Ibandronate
(Boniva)
13.6.6.1.1.3. Risedronate
(Actonel, Atelvia)
13.6.6.1.1.4. Zoledronic
acid
13.6.6.1.2. Denosumab
13.6.6.1.3. Hormone-related therapy
13.6.6.1.4. Bone-building medications
13.6.6.1.4.1. Teriparatide
13.6.6.1.4.2. Abaloparatide
13.6.6.1.4.3. Romosozumab
13.6.6.1.5. Others
13.6.6.2. Nordic Countries Osteoporosis Treatment Market Revenue (US$
Mn) and Forecasts, By Route of Administration
13.6.6.2.1. Oral
13.6.6.2.2. Intravenous
13.6.6.3. Nordic Countries Osteoporosis Treatment Market Revenue (US$
Mn) and Forecasts, By Gender
13.6.6.3.1. Men
13.6.6.3.2. Women
13.6.6.4. Nordic Countries Osteoporosis Treatment Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
13.6.6.4.1. Online Pharmacies
13.6.6.4.2. Retail Pharmacies
13.6.6.4.3. Hospitals and Clinics
13.6.6.5. Nordic Countries Osteoporosis Treatment Market Revenue (US$
Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
13.6.7.1.1. Bisphosphonates
13.6.7.1.1.1. Alendronate
(Binosto, Fosamax)
13.6.7.1.1.2. Ibandronate
(Boniva)
13.6.7.1.1.3. Risedronate
(Actonel, Atelvia)
13.6.7.1.1.4. Zoledronic
acid
13.6.7.1.2. Denosumab
13.6.7.1.3. Hormone-related therapy
13.6.7.1.4. Bone-building medications
13.6.7.1.4.1. Teriparatide
13.6.7.1.4.2. Abaloparatide
13.6.7.1.4.3. Romosozumab
13.6.7.1.5. Others
13.6.7.2. Benelux Union Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.6.7.2.1. Oral
13.6.7.2.2. Intravenous
13.6.7.3. Benelux Union Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Gender
13.6.7.3.1. Men
13.6.7.3.2. Women
13.6.7.4. Benelux Union Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
13.6.7.4.1. Online Pharmacies
13.6.7.4.2. Retail Pharmacies
13.6.7.4.3. Hospitals and Clinics
13.6.7.5. Benelux Union Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
13.6.8.1.1. Bisphosphonates
13.6.8.1.1.1. Alendronate
(Binosto, Fosamax)
13.6.8.1.1.2. Ibandronate
(Boniva)
13.6.8.1.1.3. Risedronate
(Actonel, Atelvia)
13.6.8.1.1.4. Zoledronic
acid
13.6.8.1.2. Denosumab
13.6.8.1.3. Hormone-related therapy
13.6.8.1.4. Bone-building medications
13.6.8.1.4.1. Teriparatide
13.6.8.1.4.2. Abaloparatide
13.6.8.1.4.3. Romosozumab
13.6.8.1.5. Others
13.6.8.2. Rest of Europe Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.6.8.2.1. Oral
13.6.8.2.2. Intravenous
13.6.8.3. Rest of Europe Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Gender
13.6.8.3.1. Men
13.6.8.3.2. Women
13.6.8.4. Rest of Europe Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
13.6.8.4.1. Online Pharmacies
13.6.8.4.2. Retail Pharmacies
13.6.8.4.3. Hospitals and Clinics
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Treatment
13.7.3. By
Route of Administration
13.7.4. By
Gender
13.7.5. By
Distribution Channel
14. Asia Pacific Osteoporosis Treatment Market Analysis and
Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Asia
Pacific Osteoporosis Treatment Market Revenue (US$ Mn)
14.2. Asia
Pacific Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment
14.2.1. Bisphosphonates
14.2.1.1. Alendronate (Binosto, Fosamax)
14.2.1.2. Ibandronate (Boniva)
14.2.1.3. Risedronate (Actonel, Atelvia)
14.2.1.4. Zoledronic acid
14.2.2. Denosumab
14.2.3. Hormone-related
therapy
14.2.4. Bone-building
medications
14.2.4.1. Teriparatide
14.2.4.2. Abaloparatide
14.2.4.3. Romosozumab
14.2.5. Others
14.3. Asia
Pacific Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.3.1. Oral
14.3.2. Intravenous
14.4. Asia
Pacific Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Gender
14.4.1. Men
14.4.2. Women
14.5. Asia
Pacific Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.5.1. Online
Pharmacies
14.5.2. Retail
Pharmacies
14.5.3. Hospitals
and Clinics
14.6. Asia
Pacific Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.1. China
14.6.1.1. China Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.6.1.1.1. Bisphosphonates
14.6.1.1.1.1. Alendronate
(Binosto, Fosamax)
14.6.1.1.1.2. Ibandronate
(Boniva)
14.6.1.1.1.3. Risedronate
(Actonel, Atelvia)
14.6.1.1.1.4. Zoledronic
acid
14.6.1.1.2. Denosumab
14.6.1.1.3. Hormone-related therapy
14.6.1.1.4. Bone-building medications
14.6.1.1.4.1. Teriparatide
14.6.1.1.4.2. Abaloparatide
14.6.1.1.4.3. Romosozumab
14.6.1.1.5. Others
14.6.1.2. China Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.1.2.1. Oral
14.6.1.2.2. Intravenous
14.6.1.3. China Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
14.6.1.3.1. Men
14.6.1.3.2. Women
14.6.1.4. China Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.1.4.1. Online Pharmacies
14.6.1.4.2. Retail Pharmacies
14.6.1.4.3. Hospitals and Clinics
14.6.2. Japan
14.6.2.1. Japan Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.6.2.1.1. Bisphosphonates
14.6.2.1.1.1. Alendronate
(Binosto, Fosamax)
14.6.2.1.1.2. Ibandronate
(Boniva)
14.6.2.1.1.3. Risedronate
(Actonel, Atelvia)
14.6.2.1.1.4. Zoledronic
acid
14.6.2.1.2. Denosumab
14.6.2.1.3. Hormone-related therapy
14.6.2.1.4. Bone-building medications
14.6.2.1.4.1. Teriparatide
14.6.2.1.4.2. Abaloparatide
14.6.2.1.4.3. Romosozumab
14.6.2.1.5. Others
14.6.2.2. Japan Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.2.2.1. Oral
14.6.2.2.2. Intravenous
14.6.2.3. Japan Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
14.6.2.3.1. Men
14.6.2.3.2. Women
14.6.2.4. Japan Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.2.4.1. Online Pharmacies
14.6.2.4.2. Retail Pharmacies
14.6.2.4.3. Hospitals and Clinics
14.6.3. India
14.6.3.1. India Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.6.3.1.1. Bisphosphonates
14.6.3.1.1.1. Alendronate
(Binosto, Fosamax)
14.6.3.1.1.2. Ibandronate
(Boniva)
14.6.3.1.1.3. Risedronate
(Actonel, Atelvia)
14.6.3.1.1.4. Zoledronic
acid
14.6.3.1.2. Denosumab
14.6.3.1.3. Hormone-related therapy
14.6.3.1.4. Bone-building medications
14.6.3.1.4.1. Teriparatide
14.6.3.1.4.2. Abaloparatide
14.6.3.1.4.3. Romosozumab
14.6.3.1.5. Others
14.6.3.2. India Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.3.2.1. Oral
14.6.3.2.2. Intravenous
14.6.3.3. India Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
14.6.3.3.1. Men
14.6.3.3.2. Women
14.6.3.4. India Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.3.4.1. Online Pharmacies
14.6.3.4.2. Retail Pharmacies
14.6.3.4.3. Hospitals and Clinics
14.6.4. New
Zealand
14.6.4.1. New Zealand Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.6.4.1.1. Bisphosphonates
14.6.4.1.1.1. Alendronate
(Binosto, Fosamax)
14.6.4.1.1.2. Ibandronate
(Boniva)
14.6.4.1.1.3. Risedronate
(Actonel, Atelvia)
14.6.4.1.1.4. Zoledronic
acid
14.6.4.1.2. Denosumab
14.6.4.1.3. Hormone-related therapy
14.6.4.1.4. Bone-building medications
14.6.4.1.4.1. Teriparatide
14.6.4.1.4.2. Abaloparatide
14.6.4.1.4.3. Romosozumab
14.6.4.1.5. Others
14.6.4.2. New Zealand Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.4.2.1. Oral
14.6.4.2.2. Intravenous
14.6.4.3. New Zealand Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
14.6.4.3.1. Men
14.6.4.3.2. Women
14.6.4.4. New Zealand Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.4.4.1. Online Pharmacies
14.6.4.4.2. Retail Pharmacies
14.6.4.4.3. Hospitals and Clinics
14.6.5. Australia
14.6.5.1. Australia Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.6.5.1.1. Bisphosphonates
14.6.5.1.1.1. Alendronate
(Binosto, Fosamax)
14.6.5.1.1.2. Ibandronate
(Boniva)
14.6.5.1.1.3. Risedronate
(Actonel, Atelvia)
14.6.5.1.1.4. Zoledronic
acid
14.6.5.1.2. Denosumab
14.6.5.1.3. Hormone-related therapy
14.6.5.1.4. Bone-building medications
14.6.5.1.4.1. Teriparatide
14.6.5.1.4.2. Abaloparatide
14.6.5.1.4.3. Romosozumab
14.6.5.1.5. Others
14.6.5.2. Australia Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.5.2.1. Oral
14.6.5.2.2. Intravenous
14.6.5.3. Australia Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts,
By Gender
14.6.5.3.1. Men
14.6.5.3.2. Women
14.6.5.4. Australia Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.5.4.1. Online Pharmacies
14.6.5.4.2. Retail Pharmacies
14.6.5.4.3. Hospitals and Clinics
14.6.6. South
Korea
14.6.6.1. South Korea Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
14.6.6.1.1. Bisphosphonates
14.6.6.1.1.1. Alendronate
(Binosto, Fosamax)
14.6.6.1.1.2. Ibandronate
(Boniva)
14.6.6.1.1.3. Risedronate
(Actonel, Atelvia)
14.6.6.1.1.4. Zoledronic
acid
14.6.6.1.2. Denosumab
14.6.6.1.3. Hormone-related therapy
14.6.6.1.4. Bone-building medications
14.6.6.1.4.1. Teriparatide
14.6.6.1.4.2. Abaloparatide
14.6.6.1.4.3. Romosozumab
14.6.6.1.5. Others
14.6.6.2. South Korea Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.6.2.1. Oral
14.6.6.2.2. Intravenous
14.6.6.3. South Korea Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
14.6.6.3.1. Men
14.6.6.3.2. Women
14.6.6.4. South Korea Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.6.4.1. Online Pharmacies
14.6.6.4.2. Retail Pharmacies
14.6.6.4.3. Hospitals and Clinics
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
14.6.7.1.1. Bisphosphonates
14.6.7.1.1.1. Alendronate
(Binosto, Fosamax)
14.6.7.1.1.2. Ibandronate
(Boniva)
14.6.7.1.1.3. Risedronate
(Actonel, Atelvia)
14.6.7.1.1.4. Zoledronic
acid
14.6.7.1.2. Denosumab
14.6.7.1.3. Hormone-related therapy
14.6.7.1.4. Bone-building medications
14.6.7.1.4.1. Teriparatide
14.6.7.1.4.2. Abaloparatide
14.6.7.1.4.3. Romosozumab
14.6.7.1.5. Others
14.6.7.2. Southeast Asia Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
14.6.7.2.1. Oral
14.6.7.2.2. Intravenous
14.6.7.3. Southeast Asia Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Gender
14.6.7.3.1. Men
14.6.7.3.2. Women
14.6.7.4. Southeast Asia Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
14.6.7.4.1. Online Pharmacies
14.6.7.4.2. Retail Pharmacies
14.6.7.4.3. Hospitals and Clinics
14.6.7.5. Southeast Asia Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Osteoporosis Treatment Market Revenue
(US$ Mn) and Forecasts, By Treatment
14.6.8.1.1. Bisphosphonates
14.6.8.1.1.1. Alendronate
(Binosto, Fosamax)
14.6.8.1.1.2. Ibandronate
(Boniva)
14.6.8.1.1.3. Risedronate
(Actonel, Atelvia)
14.6.8.1.1.4. Zoledronic
acid
14.6.8.1.2. Denosumab
14.6.8.1.3. Hormone-related therapy
14.6.8.1.4. Bone-building medications
14.6.8.1.4.1. Teriparatide
14.6.8.1.4.2. Abaloparatide
14.6.8.1.4.3. Romosozumab
14.6.8.1.5. Others
14.6.8.2. Rest of Asia Pacific Osteoporosis Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
14.6.8.2.1. Oral
14.6.8.2.2. Intravenous
14.6.8.3. Rest of Asia Pacific Osteoporosis Treatment Market Revenue
(US$ Mn) and Forecasts, By Gender
14.6.8.3.1. Men
14.6.8.3.2. Women
14.6.8.4. Rest of Asia Pacific Osteoporosis Treatment Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
14.6.8.4.1. Online Pharmacies
14.6.8.4.2. Retail Pharmacies
14.6.8.4.3. Hospitals and Clinics
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Treatment
14.7.3. By
Route of Administration
14.7.4. By
Gender
14.7.5. By
Distribution Channel
15. Middle East and Africa Osteoporosis Treatment Market Analysis
and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Middle
East and Africa Osteoporosis Treatment Market Revenue (US$ Mn)
15.2. Middle
East and Africa Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts,
By Treatment
15.2.1. Bisphosphonates
15.2.1.1. Alendronate (Binosto, Fosamax)
15.2.1.2. Ibandronate (Boniva)
15.2.1.3. Risedronate (Actonel, Atelvia)
15.2.1.4. Zoledronic acid
15.2.2. Denosumab
15.2.3. Hormone-related
therapy
15.2.4. Bone-building
medications
15.2.4.1. Teriparatide
15.2.4.2. Abaloparatide
15.2.4.3. Romosozumab
15.2.5. Others
15.3. Middle
East and Africa Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.3.1. Oral
15.3.2. Intravenous
15.4. Middle
East and Africa Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts,
By Gender
15.4.1. Men
15.4.2. Women
15.5. Middle
East and Africa Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
15.5.1. Online
Pharmacies
15.5.2. Retail
Pharmacies
15.5.3. Hospitals
and Clinics
15.6. Middle
East and Africa Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts,
By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
15.6.1.1.1. Bisphosphonates
15.6.1.1.1.1. Alendronate
(Binosto, Fosamax)
15.6.1.1.1.2. Ibandronate
(Boniva)
15.6.1.1.1.3. Risedronate
(Actonel, Atelvia)
15.6.1.1.1.4. Zoledronic
acid
15.6.1.1.2. Denosumab
15.6.1.1.3. Hormone-related therapy
15.6.1.1.4. Bone-building medications
15.6.1.1.4.1. Teriparatide
15.6.1.1.4.2. Abaloparatide
15.6.1.1.4.3. Romosozumab
15.6.1.1.5. Others
15.6.1.2. Saudi Arabia Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.6.1.2.1. Oral
15.6.1.2.2. Intravenous
15.6.1.3. Saudi Arabia Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Gender
15.6.1.3.1. Men
15.6.1.3.2. Women
15.6.1.4. Saudi Arabia Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
15.6.1.4.1. Online Pharmacies
15.6.1.4.2. Retail Pharmacies
15.6.1.4.3. Hospitals and Clinics
15.6.2. UAE
15.6.2.1. UAE Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
15.6.2.1.1. Bisphosphonates
15.6.2.1.1.1. Alendronate
(Binosto, Fosamax)
15.6.2.1.1.2. Ibandronate
(Boniva)
15.6.2.1.1.3. Risedronate
(Actonel, Atelvia)
15.6.2.1.1.4. Zoledronic
acid
15.6.2.1.2. Denosumab
15.6.2.1.3. Hormone-related therapy
15.6.2.1.4. Bone-building medications
15.6.2.1.4.1. Teriparatide
15.6.2.1.4.2. Abaloparatide
15.6.2.1.4.3. Romosozumab
15.6.2.1.5. Others
15.6.2.2. UAE Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.2.2.1. Oral
15.6.2.2.2. Intravenous
15.6.2.3. UAE Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
15.6.2.3.1. Men
15.6.2.3.2. Women
15.6.2.4. UAE Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.6.2.4.1. Online Pharmacies
15.6.2.4.2. Retail Pharmacies
15.6.2.4.3. Hospitals and Clinics
15.6.3. Egypt
15.6.3.1. Egypt Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
15.6.3.1.1. Bisphosphonates
15.6.3.1.1.1. Alendronate
(Binosto, Fosamax)
15.6.3.1.1.2. Ibandronate
(Boniva)
15.6.3.1.1.3. Risedronate
(Actonel, Atelvia)
15.6.3.1.1.4. Zoledronic
acid
15.6.3.1.2. Denosumab
15.6.3.1.3. Hormone-related therapy
15.6.3.1.4. Bone-building medications
15.6.3.1.4.1. Teriparatide
15.6.3.1.4.2. Abaloparatide
15.6.3.1.4.3. Romosozumab
15.6.3.1.5. Others
15.6.3.2. Egypt Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.3.2.1. Oral
15.6.3.2.2. Intravenous
15.6.3.3. Egypt Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
15.6.3.3.1. Men
15.6.3.3.2. Women
15.6.3.4. Egypt Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.6.3.4.1. Online Pharmacies
15.6.3.4.2. Retail Pharmacies
15.6.3.4.3. Hospitals and Clinics
15.6.4. Kuwait
15.6.4.1. Kuwait Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
15.6.4.1.1. Bisphosphonates
15.6.4.1.1.1. Alendronate
(Binosto, Fosamax)
15.6.4.1.1.2. Ibandronate
(Boniva)
15.6.4.1.1.3. Risedronate
(Actonel, Atelvia)
15.6.4.1.1.4. Zoledronic
acid
15.6.4.1.2. Denosumab
15.6.4.1.3. Hormone-related therapy
15.6.4.1.4. Bone-building medications
15.6.4.1.4.1. Teriparatide
15.6.4.1.4.2. Abaloparatide
15.6.4.1.4.3. Romosozumab
15.6.4.1.5. Others
15.6.4.2. Kuwait Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.4.2.1. Oral
15.6.4.2.2. Intravenous
15.6.4.3. Kuwait Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
15.6.4.3.1. Men
15.6.4.3.2. Women
15.6.4.4. Kuwait Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.6.4.4.1. Online Pharmacies
15.6.4.4.2. Retail Pharmacies
15.6.4.4.3. Hospitals and Clinics
15.6.5. South
Africa
15.6.5.1. South Africa Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Treatment
15.6.5.1.1. Bisphosphonates
15.6.5.1.1.1. Alendronate
(Binosto, Fosamax)
15.6.5.1.1.2. Ibandronate
(Boniva)
15.6.5.1.1.3. Risedronate
(Actonel, Atelvia)
15.6.5.1.1.4. Zoledronic
acid
15.6.5.1.2. Denosumab
15.6.5.1.3. Hormone-related therapy
15.6.5.1.4. Bone-building medications
15.6.5.1.4.1. Teriparatide
15.6.5.1.4.2. Abaloparatide
15.6.5.1.4.3. Romosozumab
15.6.5.1.5. Others
15.6.5.2. South Africa Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
15.6.5.2.1. Oral
15.6.5.2.2. Intravenous
15.6.5.3. South Africa Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Gender
15.6.5.3.1. Men
15.6.5.3.2. Women
15.6.5.4. South Africa Osteoporosis Treatment Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
15.6.5.4.1. Online Pharmacies
15.6.5.4.2. Retail Pharmacies
15.6.5.4.3. Hospitals and Clinics
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Osteoporosis Treatment Market
Revenue (US$ Mn) and Forecasts, By Treatment
15.6.6.1.1. Bisphosphonates
15.6.6.1.1.1. Alendronate
(Binosto, Fosamax)
15.6.6.1.1.2. Ibandronate
(Boniva)
15.6.6.1.1.3. Risedronate
(Actonel, Atelvia)
15.6.6.1.1.4. Zoledronic
acid
15.6.6.1.2. Denosumab
15.6.6.1.3. Hormone-related therapy
15.6.6.1.4. Bone-building medications
15.6.6.1.4.1. Teriparatide
15.6.6.1.4.2. Abaloparatide
15.6.6.1.4.3. Romosozumab
15.6.6.1.5. Others
15.6.6.2. Rest of Middle East & Africa Osteoporosis Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.6.2.1. Oral
15.6.6.2.2. Intravenous
15.6.6.3. Rest of Middle East & Africa Osteoporosis Treatment Market
Revenue (US$ Mn) and Forecasts, By Gender
15.6.6.3.1. Men
15.6.6.3.2. Women
15.6.6.4. Rest of Middle East & Africa Osteoporosis Treatment Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.6.4.1. Online Pharmacies
15.6.6.4.2. Retail Pharmacies
15.6.6.4.3. Hospitals and Clinics
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By
Treatment
15.7.3. By
Route of Administration
15.7.4. By
Gender
15.7.5. By
Distribution Channel
16. Latin America Osteoporosis Treatment Market Analysis and
Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Latin
America Osteoporosis Treatment Market Revenue (US$ Mn)
16.2. Latin
America Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By
Treatment
16.2.1. Bisphosphonates
16.2.1.1. Alendronate (Binosto, Fosamax)
16.2.1.2. Ibandronate (Boniva)
16.2.1.3. Risedronate (Actonel, Atelvia)
16.2.1.4. Zoledronic acid
16.2.2. Denosumab
16.2.3. Hormone-related
therapy
16.2.4. Bone-building
medications
16.2.4.1. Teriparatide
16.2.4.2. Abaloparatide
16.2.4.3. Romosozumab
16.2.5. Others
16.3. Latin
America Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
16.3.1. Oral
16.3.2. Intravenous
16.4. Latin
America Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By Gender
16.4.1. Men
16.4.2. Women
16.5. Latin
America Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.5.1. Online
Pharmacies
16.5.2. Retail
Pharmacies
16.5.3. Hospitals
and Clinics
16.6. Latin
America Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts, By
Country
16.6.1. Brazil
16.6.1.1. Brazil Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
16.6.1.1.1. Bisphosphonates
16.6.1.1.1.1. Alendronate
(Binosto, Fosamax)
16.6.1.1.1.2. Ibandronate
(Boniva)
16.6.1.1.1.3. Risedronate
(Actonel, Atelvia)
16.6.1.1.1.4. Zoledronic
acid
16.6.1.1.2. Denosumab
16.6.1.1.3. Hormone-related therapy
16.6.1.1.4. Bone-building medications
16.6.1.1.4.1. Teriparatide
16.6.1.1.4.2. Abaloparatide
16.6.1.1.4.3. Romosozumab
16.6.1.1.5. Others
16.6.1.2. Brazil Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.6.1.2.1. Oral
16.6.1.2.2. Intravenous
16.6.1.3. Brazil Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
16.6.1.3.1. Men
16.6.1.3.2. Women
16.6.1.4. Brazil Osteoporosis Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
16.6.1.4.1. Online Pharmacies
16.6.1.4.2. Retail Pharmacies
16.6.1.4.3. Hospitals and Clinics
16.6.2. Argentina
16.6.2.1. Argentina Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Treatment
16.6.2.1.1. Bisphosphonates
16.6.2.1.1.1. Alendronate
(Binosto, Fosamax)
16.6.2.1.1.2. Ibandronate
(Boniva)
16.6.2.1.1.3. Risedronate
(Actonel, Atelvia)
16.6.2.1.1.4. Zoledronic
acid
16.6.2.1.2. Denosumab
16.6.2.1.3. Hormone-related therapy
16.6.2.1.4. Bone-building medications
16.6.2.1.4.1. Teriparatide
16.6.2.1.4.2. Abaloparatide
16.6.2.1.4.3. Romosozumab
16.6.2.1.5. Others
16.6.2.2. Argentina Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.6.2.2.1. Oral
16.6.2.2.2. Intravenous
16.6.2.3. Argentina Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Gender
16.6.2.3.1. Men
16.6.2.3.2. Women
16.6.2.4. Argentina Osteoporosis Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
16.6.2.4.1. Online Pharmacies
16.6.2.4.2. Retail Pharmacies
16.6.2.4.3. Hospitals and Clinics
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Osteoporosis Treatment Market Revenue
(US$ Mn) and Forecasts, By Treatment
16.6.3.1.1. Bisphosphonates
16.6.3.1.1.1. Alendronate
(Binosto, Fosamax)
16.6.3.1.1.2. Ibandronate
(Boniva)
16.6.3.1.1.3. Risedronate
(Actonel, Atelvia)
16.6.3.1.1.4. Zoledronic
acid
16.6.3.1.2. Denosumab
16.6.3.1.3. Hormone-related therapy
16.6.3.1.4. Bone-building medications
16.6.3.1.4.1. Teriparatide
16.6.3.1.4.2. Abaloparatide
16.6.3.1.4.3. Romosozumab
16.6.3.1.5. Others
16.6.3.2. Rest of Latin America Osteoporosis Treatment Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
16.6.3.2.1. Oral
16.6.3.2.2. Intravenous
16.6.3.3. Rest of Latin America Osteoporosis Treatment Market Revenue
(US$ Mn) and Forecasts, By Gender
16.6.3.3.1. Men
16.6.3.3.2. Women
16.6.3.4. Rest of Latin America Osteoporosis Treatment Market Revenue
(US$ Mn) and Forecasts, By Distribution Channel
16.6.3.4.1. Online Pharmacies
16.6.3.4.2. Retail Pharmacies
16.6.3.4.3. Hospitals and Clinics
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Treatment
16.7.3. By
Route of Administration
16.7.4. By
Gender
16.7.5. By
Distribution Channel
17. Competitive Benchmarking
17.1. Brand
Benchmarking
17.2. Market
Share Analysis, 2021
17.3. Global
Presence and Growth Strategies
17.3.1. Mergers
and Acquisitions
17.3.2. Product
Launches
17.3.3. Investments
Trends
17.3.4. R&D
Initiatives
18. Player Profiles
18.1. Amgen Inc
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. DAIICHI SANKYO COMPANY, LIMITED
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. Eli Lilly and Company
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. F. Hoffmann-La Roche Ltd
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. Ligand Pharmaceuticals Incorporated
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. Merck & Co., Inc
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Novartis AG
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Pfizer Inc.
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Radius Health, Inc.
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Sanofi-aventis U.S. LLC
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. Teva Pharmaceuticals Industries Ltd.
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. Other
Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.